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Abstract: Findings from epidemiological and observational studies have indicated that 
diets high in omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA) may reduce the risk of cognitive decline and 
Alzheimer’s disease (AD). To determine if increasing intake of DHA and EPA through 
supplementation is beneficial to cognition and mood in individuals with cognitive 
impairment no dementia (CIND) or Alzheimer’s disease (AD) a four month, randomised, 
double-blind, placebo controlled study was conducted. Fifty-seven participants with CIND 
and nineteen with AD were randomised to receive either omega-3 PUFAs (600 mg EPA 
and 625 mg DHA per day) or placebo (olive oil) over a four month period. Elevating 
depleted levels of EPA and DHA through supplementation in individuals with CIND or 
AD was found to have negligible beneficial effect on their cognition or mood. These 
findings confirm an overall negligible benefit of omega-3 PUFA supplementation for those 
with cognitive impairment and dementia. More intervention studies need to be undertaken 
with longer study durations and larger sample sizes. It may prove fruitful to examine 
effects of different doses as well as effects in other dementia subtypes. 
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1. Introduction 
There is increasing scientific evidence from epidemiology and animal studies linking omega-3 
polyunsaturated fatty acid (PUFA) intake with physical health [1–5]. Evidence is also being 
accumulated which suggests beneficial links between diets high in omega-3 PUFAs and reduced risk 
of cognitive decline and dementia [6]. With dementia fast becoming a global epidemic, it is clear that  
a major effort is needed to identify preventative and therapeutic strategies to alleviate the burden of 
cognitive decline and dementia. Diet, specifically omega-3 PUFAs, may beneficially modify risk 
factors in the aetiology of dementia [6]. 
Few intervention studies have investigated whether omega-3 PUFAs are beneficial to cognition in 
either healthy older adults or in older adults with a clinical diagnosis of dementia, specifically 
Alzheimer’s disease (AD) and, even less explored, cognitive impairment no dementia (CIND) [7].  
The few studies that have been conducted report equivocal results. Improvements in Mini Mental State 
Examination (MMSE) score and quality of life were found when supplementing EPA or a combination 
of omega-3 and -6 PUFAs to patients with AD [8,9]. However another study contradicted these 
findings [10]. More recently, a larger randomised double-blind placebo controlled study, which found 
that supplementing DHA and EPA along with cholinesterase inhibitors to mild to moderate AD 
patients did not improve or delay the progression of cognitive decline [11]. However, positive effects 
were found in a small sub-group of mild AD patients who scored >27 on the MMSE. It has been 
reported that such an intervention did show positive effects on depressive and agitation symptoms in 
non-APOE carriers and APOE carriers, respectively [12]. This is the only published piece of work that 
has examined the benefits of such an intervention on the mood of individuals with AD. No published 
data exist about the benefits omega-3 PUFAs may have on mood in individuals with CIND, although 
there is a fairly large literature on effects of omega-3 PUFA supplementation in depression [13]. 
Moreover, there may also be potential benefits of omega-3 PUFA supplementation on cognition in 
individuals with mild cognitive difficulties [7]. Treatment benefits in Mild Cognitive Impairment 
(MCI) participants have been found but there was no benefit in AD patients [7,14,15]. There are other 
high quality studies published in this topic area [16–19]; however we were specifically concerned with 
studies recruiting individuals with clinical diagnoses of dementia of which there are still very few. 
Therefore, the present randomised, double-blind placebo-controlled study explored whether omega-3 
PUFA supplements providing DHA and EPA benefit cognition and mood in individuals with early 
stage AD and CIND, rather than moderately impaired AD patients. 
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2. Results 
2.1. Participant Characteristics 
Seventy six individuals (57 CIND and 19 AD) were recruited and there were no dropouts. However, 
four participants (2 CIND randomised to placebo and 2 AD, one randomised to omega-3 supplements 
and one to placebo) did not complete all visits. Reasons for non-attendance were illness or hospital 
admission. Details of the demographic characteristics of the participants receiving omega-3 
supplements or placebo are shown in Table 1. Data for individuals with CIND or with AD are 
combined due to the low recruitment in the latter population. 
Table 1. Characteristics of participants in the omega-3 fatty acid and placebo groups at 
study entry. 
Characteristic Total Group 
Omega-3 PUFA Group 
(n = 37) 
Placebo Group 
(n = 39) 
Female, n (%) 42 (55.3) 21 (56.8) 21 (53.8) 
Age, y (SD) 71.1 (4.8) 71.1 (8.6) 71.1 (9.5) 
Education, y (SD) 14.1 (4.8) 14.3 (5.1) 13.8 (4.5) 
NART IQ (SD) 110 (10) 108 (9) 111 (11) 
Baseline EPA 1.51 (1.15) 1.58 (1.31) 1.44 (0.99) 
Baseline DHA 3.98 (1.12) 4.06 (1.14) 3.91 (1.12) 
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; n, number; NART IQ, National Adult Reading 
Test Intelligence Quotient; y, years. 
There were no differences in age, years of education and pre-morbid (NART) IQ [20] between  
the two treatment groups at study entry. Participants with AD continued to receive a stable dose of  
a cholinesterase inhibitor for the duration of the study. 
2.2. Compliance and Plasma Phosphatidylcholine (PC) Fatty Acids 
Compliance was measured by capsule count and plasma PC fatty acid concentrations. On average 
both groups consumed 75.6% (SD 0.8) of their capsules. 
Plasma PC EPA and DHA did not change in the placebo group (Figure 1). However, they both 
increased at month 1 in the omega-3 group (both p < 0.00001 vs. baseline, respectively) (Figure 1). 
There was no further increase to month 4 (Figure 1). Both EPA and DHA were higher in the omega-3 
PUFA group than in the placebo group at months 1 and 4 (Figure 1). The mean increase in EPA in the 
omega-3 group was 137.5% and for DHA it was 38.1%. 
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Figure 1. Plasma phosphatidylcholine EPA and DHA in the omega-3 and placebo groups at 
baseline, and after one and four months of treatment. Error bars are for total fatty acids (EPA 
+ DHA). DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PC, phosphatidylcholine. 
2.3. Primary Outcome 
There were two participants (1 CIND, 1 AD) who did not attend their month 4 appointment.  
In these cases, the missing data were replaced using last observation carried forward. No differences in 
baseline performance scores for any of the six primary outcome measures between the omega-3 PUFA 
and placebo groups were found (p > 0.158) These scores were subsequently unaffected by omega-3 
PUFAs: there was no significant effect of treatment or significant treatment by month interaction for 
any of the outcomes (Table 2). 
Table 2. Primary outcome measure performance scores over the study duration. Data  
are mean (SD). Baseline scores were included as a covariate in the analyses of the  
effects of treatment and treatment by month. MMSES7, mini–mental state examination 
Serial Sevens; MMSEWB, mini–mental state examination World Backwards; PUFA, 
polyunsaturated fatty acid. 
Outcome Measure 
Omega-3  
PUFA Group 
Placebo Group 
p for Main Effect of 
Treatment 
p for Treatment by Month 
Interaction 
MMSES7 
Baseline 24.3 (3.2) 23.4 (4.1) 
F (1,73) < 1, p = 0.711 F (1,73) < 1, p = 0.959 Month 1 24.4 (3.9) 23.4 (4.6) 
Month 4 24.4 (4.1) 23.3 (4.7) 
MMSEWB 
Baseline 25.0 (2.8) 24.2 (3.7) 
F (1,73) < 1, p = 0.576 F (1,73) < 1, p = 0.750 Month 1 25.3 (3.4) 24.2 (3.8) 
Month 4 25.3 (3.4) 23.3 (4.1) 
Immediate 
verbal memory 
Baseline 16.2 (4.3) 16.0 (5.9) 
F (1,73) = 0.461, p = 0.499 F (1,73) = 0.567, p = 0.454 Month 1 17.4 (5.1) 17.4 (6.7) 
Month 4 16.1 (5.2) 16.7 (6.3) 
Delayed verbal 
memory 
Baseline 3.5 (2.7) 3.1 (3.0) 
F (1,73) < 1, p = 0.463 F (1,73) < 1, p = 0.998 Month 1 3.9 (3.1) 3.9 (3.3) 
Month 4 3.4 (2.9) 3.5 (3.2) 
Recognition 
verbal memory 
Baseline 6.4 (3.3) 6.4 (3.6) 
F (1,73) < 1, p = 0.463 F (1,73) = 1.67, p = 0.200 Month 1 7.4 (3.8) 7.3 (3.8) 
Month 4 7.1 (3.4) 6.3 (4.1) 
Mood 
Baseline 2.7 (2.4) 2.3 (2.0) 
F (1,73) < 1, p = 0.548 F (1,73) < 1, p = 0.468 Month 1 2.3 (3.2) 2.3 (3.1) 
Month 4 2.3 (2.9) 2.1 (2.5) 
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2.4. Secondary Outcome Measures 
There were no significant effects of treatment for any secondary outcome measures (Table 3). In 
addition, there were no treatment by month interactions. 
Table 3. Secondary outcome measure performance scores over the study duration. 
BADLS, Bristol’s Activities of Daily Living Scale; CLOX2, clock drawing task 2; PUFA, 
polyunsaturated fatty acid. 
Outcome Measure 
Omega-3  
PUFA Group 
Placebo Group 
F and p Values for Main 
Effect of Treatment 
F and p for Treatment by 
Month Interaction 
Verbal 
reasoning 
Baseline 18.8 (6.0) 18.8 (6.4) 
F (1,73) = 2.45, p = 0.122 F (1,73) = 1.28, p = 0.262 Month 1 19.8 (5.9) 19.2 (6.7) 
Month 4 20.1 (6.2) 18.6 (7.6) 
Visual memory 
Baseline 9.72 (4.12) 9.08 (4.05) 
F (1,73) = 2.87, p = 0.095 F (1,73) < 1, p = 0.863 Month 1 10.75 (2.89) 9.41 (4.59) 
Month 4 11.31 (4.27) 9.82 (4.07) 
CLOX2  
(Executive 
function) 
Baseline 13.8 (1.2) 13.4 (1.3) 
F (1,73) < 1, p = 0.359 F (1,73) < 1, p = 0.551 Month 1 13.8 (1.2) 14.0 (1.3) 
Month 4 13.6 (1.8) 13.5 (1.9) 
Word finding 
Baseline 13.0 (2.3) 12.4 (3.2) 
F (1,73) = 1.15, p = 0.288 F (1,73) < 1, p = 0.695 Month 1 13.4 (2.1) 12.6 (3.1) 
Month 4 13.5 (2.5) 12.9 (2.9) 
BADLS 
Baseline 2.62(5.28) 4.72 (7.34) 
F (1,73) < 1, p = 0.595 F (1,73) < 1, p = 0.965 Month 1 2.92 (5.61) 4.77 (7.11) 
Month 4 3.35 (7.10) 5.38 (8.07) 
Data are mean (SD). Baseline scores were included as a covariate in the analyses of the effects of treatment 
and treatment by month. 
3. Discussion 
Although supplementation with omega-3 PUFAs raised plasma DHA and EPA concentrations,  
no significant treatment effects or treatment by month effects were found for any of the measures of 
cognitive function and mood. Among the six primary and five secondary outcomes only one effect, for 
visual memory, approached statistical significance. Although this was in favour of the omega-3 PUFA 
treatment, given the number of tests conducted, this can be regarded as a chance finding. Therefore, it 
can be concluded that this study found no evidence to support the suggestion that elevating omega-3 
fatty acid status in individuals with CIND and early AD using omega-3 supplements has any benefit to 
their cognition or mood. It may also be possible to speculate that similar results would be replicated in 
a clinical sample of individuals with MCI. Therefore, the clinical usefulness of such an intervention  
is questionable. 
The findings from this randomised, double-blind, placebo controlled study found that elevating 
omega-3 fatty acid levels in individuals with CIND and early AD does not benefit cognition or mood 
both support and contradict previous intervention studies in this area [7–9,21]. These findings support 
other research evidence [10,11,22] which stated that individuals with mild to moderate AD do not 
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benefit from such an intervention. However, the findings from this study contradict other research 
evidence that individuals with very mild AD may benefit from omega-3 fatty acid supplements 
because they reduce the rate of decline in MMSE score and improve symptoms of depression and 
agitation [11,12]. However, the present study did not obtain data relating to whether participants were 
APOE4 carriers. Therefore, it is not possible to completely contradict the earlier findings which 
indicated that depressive symptoms were reduced by omega-3 fatty acids in non-APOE4 carriers.  
This study also contradicts the suggestions that this type of intervention improves cognition in those 
with MCI [7,13,15]. It is therefore clear that evidence remains equivocal at this time especially when 
the majority of intervention studies have relatively small sample sizes. Therefore, future research 
programmes in this area need to undertake much larger studies with larger samples sizes and longer 
study durations. 
Although the supplement used contained similar amounts of EPA and DHA, the relative increase in 
the content of EPA in plasma PC from baseline was much greater than the relative increase in the 
content of DHA (mean increases 137.5% and 38.1%, respectively). However, this reflects an absolute 
increase in EPA content of 2% of fatty acids (from ~1.5% of fatty acids at baseline to ~3.5% after 
supplementation) and in DHA content of 1.5% of fatty acids (from ~4% of fatty acids at baseline to 
~5.5% of fatty acids after supplementation). Nevertheless, EPA seems to be better incorporated than 
DHA into plasma PC. This conclusion is consistent with previous reports. Provision of 3 g of EPA and 
3.54 g of DHA per week for one year in healthy volunteers resulted in a mean 85% relative increase in 
EPA content of plasma PC from baseline and a mean 44% relative increase in DHA content [23]. This 
greater relative uptake of EPA than DHA into plasma PC may reflect favoured metabolism of EPA 
into plasma PC or it may reflect preferential metabolic partitioning of DHA away from plasma PC and 
into other lipids. 
From the results of this study it is possible to surmise that omega-3 fatty acid supplements may 
have a negligible benefit and thus no clinical usefulness in individuals with AD and may also not be 
beneficial in primary prevention and thus not useful in people with CIND. However, there are other 
theoretical reasons why benefits were not seen in these particular populations. Firstly, in an 
unpublished poster of a research project undertaken in AD mouse models the authors argued that it 
was possible that a study duration of four months does not give the omega-3 fatty acids enough time to 
show effects on amyloid accumulation, inflammatory mediators and protein expression [24]. The authors 
of this poster argued that omega-3 fatty acids may have reduced amyloid accumulation, inflammatory 
mediators and proteinase expression but these reductions may not have lead to improvements in 
cognition and further, may not have reached the brain so behavioural or biochemical ameliorations 
could not occur [24]. The poster indicated the possibility that the amyloid precursor protein (APP) 
expression may be so high that the omega-3 fatty acids effect may not have been detectable [24].  
It is also possible that supplementation did not result in improvements to the composition of cell 
membranes leading to regeneration of nerve cells and thus improvements in cognition [25]. 
It may also be important to consider that AD is a progressive disorder where cognition is  
always deteriorating. Therefore, any improvements experienced as a result of intervention may be 
continuously overcome by the disease progression. A similar view has been argued that omega-3 fatty 
acids may have a role in primary prevention of AD but not in treatment of the disease once it has 
manifested [11]. It has also be postulated that there is a possibility that once AD is clinically evident, 
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the neuropathologic involvement is too advanced to be attenuated substantially by anti-inflammatory 
treatments [11]. Furthermore, it has been argued that there may be a critical 2-year period before the 
AD onset when inflammatory mediators are elevated [26]. Unfortunately, inflammatory mediators 
were not measured in the present study. On reflection it would have been of value to have ascertained 
whether the CIND participants had early signs of increased inflammation and if so whether they could 
be attenuated with omega-3 fatty acid supplements. Conversely, it may also be the case that such an 
intervention needs to be offered at an even earlier stage than CIND. It may be wise to undertake 
studies with individuals in mid to old age who display no cognitive deficits and show no evidence of 
elevated inflammatory mediators. 
Finally, there is a large body of evidence to suggest that the appropriate omega-3 to omega-6 ratio 
may be the important factor to normal functioning. Even though improvements to the ratio of omega-3 
fatty acids to omega-6 fatty acids through supplementation were made in this study [27], this did not 
seem to benefit cognition and mood in individuals with CIND and early AD. However, it has been 
postulated that the optimal ratio of omega-3 to 6 may vary depending on the disease of interest [28]. 
Reasons for this relate to the fact that diseases are multigenic and multifactorial. Therefore, therapeutic 
dose may depend on severity of disease taking into account possible genetic predispositions [28,29]. 
For that reason it may be necessary to design an intervention study that allocates different doses to 
individuals with varying degrees of cognitive decline. Therefore, those with CIND would be given a 
lower dose than those with AD. 
In addition to other theoretical explanations for the present findings there are some limitations 
evident in this study that need consideration. Firstly, as mentioned above, the sample size was small 
particularly for the AD group. We acknowledge that this is a limitation. However, we believe that the 
findings from this study still contribute to the body of evidence (including meta-analyses) trying to 
determine the benefits of omega-3 fatty acids in cognition and mood in demented and non-demented 
individuals. In addition, there were a few measures used in this study that may have lacked the 
sensitivity necessary for detecting change. This was particularly true for the mood measure (BASDEC) 
and the BADLS. Both were subject to ceiling affects. In retrospect, the BASDEC may have been 
inappropriate to use with individuals with AD who lack awareness and the BADLS was inappropriate 
to ascertain real change in functioning in individuals with CIND. It may have been more appropriate 
for the study partners of the CIND participants to complete the Alzheimer’s disease Cooperative Study 
scale for activities of daily living in MCI (ADCS-MCI-ADL) [30], which ascertains deficits in more 
complex everyday tasks. 
In summary, findings from this study suggest that even though omega-3 fatty acid supplementation 
elevates plasma concentrations of DHA and EPA in individuals with CIND and AD, this does not 
benefit cognition and mood in these populations. In future, studies carried out in this area should use 
larger sample sizes and longer study durations. Particular attention should also be paid to dose (with 
regards to the disease of interest, cognitive severity or dementia subtype). It is also imperative that 
cognitive and mood measures are chosen with caution to overcome issues surrounding sensitivity to 
change and ceiling and floor affects. In conclusion, at the current time it remains unclear whether the 
treatment of cognitive impairment and AD with omega-3 fatty acid supplements is beneficial and 
therefore clinically worthwhile. 
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4. Experimental Section 
4.1. Participants 
The study was conducted between February 2006 and March 2008. In total, 76 participants  
(57 individuals with CIND and 19 with AD) were recruited. The patients with AD were recruited 
though specialist memory clinics in Bristol, UK. The CIND participants were recruited from the 
community via local newspaper and radio adverts. All research procedures adhered to the Helsinki 
Declaration (1975) and good clinical practice. Ethics approval for the study was obtained from 
Frenchay Research Ethics Committee, North Bristol NHS Trust on 31 October 2005 (05/Q2007/69). 
Informed consent was obtained from all participants as well as carer assent where necessary. Figure 2 
summarises the recruitment and progress of these participants through the study. The inclusion criteria 
used were as follows: 
AD: (1) Diagnosis based on the NINCDS-ADRDA (1984) criteria [31]; (2) Have been on a stable 
dose of a cholinesterase inhibitor for a minimum of three months prior to entering the study;  
(3) MMSE score between 16 and 30.  
CIND: (1) Self report or informant-based report of cognitive change; (2) Objective cognitive 
deficits falling below age-appropriate levels (Z score of −1.5); (3) An absence of dementia; (4) Retain 
ability to perform activities of daily living; (5) Other possible neurological or psychiatric conditions 
excluded. The research criteria were based on a combination of criteria for Age-associated Cognitive 
Decline (AACD) [32,33] criteria for all three Mild Cognitive Impairment (MCI) subtypes (amnestic 
MCI, multi-domain and single non-memory domain MCI). 
Potential participants were excluded if (1) Another dementia was suspected, e.g., Dementia with 
Lewy Bodies (DLB); (2) They had a history of other psychiatric (e.g., depression (BASDEC score 
above ≥8), schizophrenia, etc.) or neurological conditions (e.g., stroke, epilepsy etc.); (3) They had a 
current drug or alcohol addiction; (4) They had disabilities, disorders or specialist dietary needs that 
would prevent all of the study’s requirements from being undertaken; (5) They were already taking 
omega-3 PUFA supplements; (6) They did not have a relative or friend that could accompany them to 
research visits and who lived with them or visited them at least 2 times a week. 
4.2. Procedures and Study Design 
A consecutive sampling design was used to recruit all participants to the two groups (AD and 
CIND). This allowed the study findings to be representative of the population from which it  
was drawn. 
Nineteen patients (11 female, 8 male) were recruited having already had a full medical and 
neuropsychological examination at one of the memory clinics based in Bristol, UK. In support of their 
diagnosis based on the NINCDS-ADRDA (1984) criteria [31], and as part of their routine clinical care, 
the majority of the AD cases had already had a computed tomography or magnetic resonance image 
taken of their brain. Routine blood analyses were also made to discount other possible causes of their 
cognitive deficits. All participants came to their research appointments with a relative or friend who 
either lived with them or who visited them at their home on a regular basis (at least two times a week). 
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Fifty-seven older adults (31 female, 26 male) with a worsening memory or thinking ability were 
recruited from the general public through a University of Bristol press release, posters in GP surgeries 
as well as newspaper adverts. All 57 CIND participants were screened for suitability by the researchers 
using a medical questionnaire developed and based around relevant medical details obtained during 
diagnostic consultations at the specialist memory clinics. None of the CIND participants had 
previously been given a diagnosis of dementia. 
 
Figure 2. Flow diagram of progress of participants through the study. 
Potential participants or their carer were sent two information sheets about the study, one 
information sheet for them and the second for their study partner (a spouse, family member or close 
friend who knew them well and who visited them at least twice a week during the week). After one 
week, they were contacted by phone to determine their interest in taking part. Participants were invited 
to attend either 3 (AD group) or 4 (CIND group) research appointments. The first was a screening 
appointment and the second, was a baseline appointment; both appointments lasted approximately one 
hour. The AD participants were not required to attend a screening appointment as all relevant 
screening documentation was gathered from their medical records once they had been approached to 
take part in the study by their treatment team. The last two appointments, which measured performance 
change from baseline took approximately one and a half to two hours each. The participants took part 
in the study for 4 months. 
Participants were randomised to receive two capsules containing a total of 625 mg DHA and  
600 mg EPA, or two placebo capsules containing olive oil each day for four months. Each capsule 
(EPA + DHA and placebo) also contained 10 mg mixed tocopherols. Participants were requested to 
219 Excluded
76 (57 CIND, 19 AD) randomised
to omega-3 fatty acid treatment or 
placebo
37 (29 CIND, 8 AD) randomised
to omega-3 fatty acid treatment 
(DHA + EPA) group
39 (28 CIND, 11 AD) randomised
to placebo (olive oil) group
0 dropped out but 1 AD participant 
did not attend all of their research 
visits
0 dropped out but 2 CIND and 1 
AD participants did not attend all 
of their research visits
37 (29 CIND, 8 AD) completed the 
omega-3 fatty acid arm treatment
39 (28 CIND, 11 AD) completed 
the placebo arm treatment
Number of individuals approached: 295  
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take the capsules at a convenient time of day for them, preferably with food. This information, as  
well as their participant ID, visit number and date of visit was also printed on a label attached to the  
outside of each container. Participants and their carers and the researchers conducting the cognitive 
assessments and the plasma fatty-acid assays were blind to the identity of the treatments (EPA + DHA 
or placebo). 
At baseline, month 1 and month 4 the following examinations were completed: fasting bloods, 
assessment of functioning in daily living, cognition, mood and visual attention. Blood samples were 
taken to assess compliance with the intervention. This, the fatty acid profile of plasma phosphatidylcholine 
(PC) was analysed by gas chromatography. Total lipid was extracted from plasma using  
chloroform-methanol (2:1 v/v). PC was isolated by solid phase extraction. Fatty acid methyl esters 
were prepared by incubation of purified plasma PC with methanol in sulphuric acid and were separated 
using a Hewlett Packard 6890 gas chromatograph (Agilent, Cheshire, UK) equipped with a 30 m × 
0.25 µm × 0.25 mm BPX-70 fused silica capillary column (SGE, Milton Keynes, UK) and flame 
ionisation detection. The concentrations of individual fatty acids in plasma PC were determined by 
measurement of the peak area using ChemStation software (Agilent) and each fatty acid was expressed 
as a proportion of the total [34]. Calculations were based on percentage contribution each fatty acid 
makes to the total fatty acids identified in plasma PC. In total, 25 fatty acids were identified which 
accounted for 99% of the peaks found in a human plasma PC gas chromatography trace. 
All participants self-reported that they had normal or corrected to normal vision and hearing. 
4.3. Consent 
Consent from both the participant and their study partner was obtained at the screening appointment 
or at the baseline appointment for the AD group. Copies of the consent and assent forms were given  
to the participants and study partners to remind them of their role and their rights to withdraw. 
Furthermore, a copy of the consent forms for the AD participants was also filed with their medical 
records. This was an ethical requirement under the terms of the project’s research ethics application. 
4.4. Outcome Measures 
The primary outcome variables used within this study were the MMSE [35], the Hopkins Verbal 
Learning Test—Revised (HVLT-R) [36] and the Brief Assessment Schedule Depression Cards 
(BASDEC) [37]. The secondary outcome variables were other neurospsychological measures such as 
tests looking at executive functioning [38], language [39], verbal reasoning [40], visual memory [41], 
as well as the Bristol’s Activities of Daily Living Scale (BADLS) [42]. 
4.5. Statistical Analysis 
Two types of analysis were conducted; intention to treat (using the last observation carried forward 
(LOCF) method) and per-protocol. Very few differences in results were observed between the two 
analyses, therefore the data presented here represent the LOCF method unless otherwise stated. 
Longitudinal changes in the outcome variables were analysed using repeated measures analysis of 
variance. The data are shown as means, standard deviations, and 95% confidence intervals. 
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4.6. Ethical Considerations 
This study abided by all the appropriate ethical guidelines outlined by the Declaration of Helsinki 
and was undertaken according to good clinical practice. Informed consent was obtained from all 
participants and assent obtained from their study partner. This study was approved by the Local Ethics 
Committee of North Bristol NHS Trust, Bristol UK and approved by the Research and Development 
departments of Avon and Wiltshire Mental Health Partnership Trust (AWP) and Bristol Primary Care 
Trust. The sponsor of the study was the University of Bristol. 
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